Search Result

Results for "

liver injury diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (41) 5-HT Receptor (3) Adrenergic Receptor (3) Akt (5) AMPK (4) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (14) ASK1 (1) Autophagy (9) Bacterial (1) Bcl-2 Family (2) Biochemical Assay Reagents (1) Calcium Channel (1) CaMK (1) Caspase (4) CDK (3) COX (1) CXCR (1) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (3) Cytochrome P450 (2) Dopamine Receptor (3) Endogenous Metabolite (1) ERK (3) Estrogen Receptor/ERR (2) Ferroptosis (1) FOXO (1) Fungal (2) FXR (1) G Protein-coupled Receptor Kinase (GRK) (1) Galectin (1) Glutathione S-transferase (1) Glycosidase (1) GSK-3 (2) HBV (1) HCV (1) Histamine Receptor (3) HSP (1) Influenza Virus (1) Interleukin Related (8) IRE1 (1) JAK (3) JNK (2) Keap1-Nrf2 (3) Lactate Dehydrogenase (1) LPL Receptor (1) LRRK2 (2) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) mTOR (1) NF-κB (9) NO Synthase (2) NOD-like Receptor (NLR) (4) P-glycoprotein (1) p38 MAPK (3) Parasite (2) PARP (2) Phospholipase (1) PI3K (3) PPAR (2) Pyroptosis (3) Reactive Oxygen Species (ROS) (7) Reference Standards (3) Sirtuin (2) SOD (1) STAT (4) TGF-β Receptor (1) TNF Receptor (2) TNK1 (2) β-catenin (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (5) Endocrinology (3) Infection (5) Inflammation/Immunology (24) Metabolic Disease (53) Neurological Disease (14)

By Targets:

17β-HSD (41)

5-HT Receptor (3)

Adrenergic Receptor (3)

Akt (5)

AMPK (4)

Amyloid-β (1)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (14)

ASK1 (1)

Autophagy (9)

Bacterial (1)

Bcl-2 Family (2)

Biochemical Assay Reagents (1)

Calcium Channel (1)

CaMK (1)

Caspase (4)

CDK (3)

COX (1)

CXCR (1)

Cyclin G-associated Kinase (GAK) (1)

Cyclophilin (3)

Cytochrome P450 (2)

Dopamine Receptor (3)

Endogenous Metabolite (1)

ERK (3)

Estrogen Receptor/ERR (2)

Ferroptosis (1)

FOXO (1)

Fungal (2)

FXR (1)

G Protein-coupled Receptor Kinase (GRK) (1)

Galectin (1)

Glutathione S-transferase (1)

Glycosidase (1)

GSK-3 (2)

HBV (1)

HCV (1)

Histamine Receptor (3)

HSP (1)

Influenza Virus (1)

Interleukin Related (8)

IRE1 (1)

JAK (3)

JNK (2)

Keap1-Nrf2 (3)

Lactate Dehydrogenase (1)

LPL Receptor (1)

LRRK2 (2)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

mTOR (1)

NF-κB (9)

NO Synthase (2)

NOD-like Receptor (NLR) (4)

P-glycoprotein (1)

p38 MAPK (3)

Parasite (2)

PARP (2)

Phospholipase (1)

PI3K (3)

PPAR (2)

Pyroptosis (3)

Reactive Oxygen Species (ROS) (7)

Reference Standards (3)

Sirtuin (2)

SOD (1)

STAT (4)

TGF-β Receptor (1)

TNF Receptor (2)

TNK1 (2)

β-catenin (1)

By Research Areas:

Cancer (14)

Cardiovascular Disease (5)

Endocrinology (3)

Infection (5)

Inflammation/Immunology (24)

Metabolic Disease (53)

Neurological Disease (14)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145801

XT2 1 Publications Verification	NF-κB	Inflammation/Immunology
XT2 is a potent, orally active, and selective inhibitor of NF-κB-inducing kinase (NIK) with an IC₅₀ of 9.1 nM. XT2 suppresses CCl4-induced upregulation of ALT, a key biomarker of acute liver injury. XT2 also decreases immune cell infiltration into the injured liver tissue. XT2 has the potential for the research of liver inflammatory diseases . XT2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-121983

CAY10594	Phospholipase Apoptosis GSK-3 Anaplastic lymphoma kinase (ALK) STAT Interleukin Related G Protein-coupled Receptor Kinase (GRK) CXCR Lactate Dehydrogenase	Inflammation/Immunology Cancer
CAY10594 is an orally active PLD2 inhibitor with an IC₅₀ of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis .

HY-168332

FXR agonist 11	FXR	Metabolic Disease
FXR agonist 11 (Compound 14) is an FXR agonist with an EC₅₀ of 1.2 μM and a maximum effect of 73.7%. FXR agonist 11 can significantly increase GSH levels in the liver and is used to study drug-induced liver injury diseases .

HY-162220

HSD17B13-IN-94	Estrogen Receptor/ERR 17β-HSD	Metabolic Disease
HSD17B13-IN-94 (Compound 12) is an effective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for Estradiol (HY-B0141). HSD17B13-IN-94 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD, NASH, or drug-induced liver injury (DILI) .

HY-171857

Cytaphat	Reactive Oxygen Species (ROS)	Metabolic Disease Inflammation/Immunology
Cytaphat is a compound with hepatoprotective activity. Cytaphat has antioxidant, membrane-stabilizing and choleretic effects. Cytaphat can be used in the research of diseases such as acute toxic hepatopathy and liver injury .

HY-162209

HSD17B13-IN-63	17β-HSD	Metabolic Disease
HSD17B13-IN-63 (Compound 160) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-63 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163254

HSD17B13-IN-57	17β-HSD	Metabolic Disease
HSD17B13-IN-57 (Compound 93) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-57 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162210

HSD17B13-IN-65	17β-HSD	Metabolic Disease
HSD17B13-IN-65 (Compound 168) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-65 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162208

HSD17B13-IN-55	17β-HSD	Metabolic Disease
HSD17B13-IN-55 (Compound 167) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-55 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163258

HSD17B13-IN-61	17β-HSD	Metabolic Disease
HSD17B13-IN-61 (Compound 132) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-61 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163243

HSD17B13-IN-29	17β-HSD	Metabolic Disease
HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163249

HSD17B13-IN-49	17β-HSD	Metabolic Disease
HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-161229

HSD17B13-IN-69	17β-HSD	Metabolic Disease
HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162213

HSD17B13-IN-86	17β-HSD	Metabolic Disease
HSD17B13-IN-86 (Compound 188) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-86 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163251

HSD17B13-IN-52	17β-HSD	Metabolic Disease
HSD17B13-IN-52 (Compound 84) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-52 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163261

HSD17B13-IN-66	17β-HSD	Metabolic Disease
HSD17B13-IN-66 (Compound 146) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-66 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-161230

HSD17B13-IN-75	17β-HSD	Metabolic Disease
HSD17B13-IN-75 (Compound 21) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-75 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163263

HSD17B13-IN-80	17β-HSD	Metabolic Disease
HSD17B13-IN-80 (Compound 151) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163264

HSD17B13-IN-81	17β-HSD	Metabolic Disease
HSD17B13-IN-81 (Compound 154) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-81 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-157662

HSD17B13-IN-33	17β-HSD	Metabolic Disease
HSD17B13-IN-33 (Compound 115) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-33 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163252

HSD17B13-IN-53	17β-HSD	Metabolic Disease
HSD17B13-IN-53 (Compound 88) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-53 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163266

HSD17B13-IN-83	17β-HSD	Metabolic Disease
HSD17B13-IN-83 (Compound 150) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-83 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163253

HSD17B13-IN-56	17β-HSD	Metabolic Disease
HSD17B13-IN-56 (Compound 89) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163250

HSD17B13-IN-51	17β-HSD	Metabolic Disease
HSD17B13-IN-51 (Compound 82) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-51 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-161228

HSD17B13-IN-48	17β-HSD	Metabolic Disease
HSD17B13-IN-48 (Compound 12) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-48 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163265

HSD17B13-IN-82	17β-HSD	Metabolic Disease
HSD17B13-IN-82 (Compound 156) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-82 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163262

HSD17B13-IN-71	17β-HSD	Metabolic Disease
HSD17B13-IN-71 (Compound 149) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-71 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162207

HSD17B13-IN-54	17β-HSD	Metabolic Disease
HSD17B13-IN-54 (Compound 158) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-54 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-161232

HSD17B13-IN-79	17β-HSD	Metabolic Disease
HSD17B13-IN-79 (Compound 32) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-79 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163260

HSD17B13-IN-64	17β-HSD	Metabolic Disease
HSD17B13-IN-64 (Compound 143) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-64 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162225

HSD17B13-IN-99	17β-HSD	Metabolic Disease
HSD17B13-IN-99 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of < 0.1 μM for estradiol. HSD17B13-IN-99 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163257

HSD17B13-IN-60	17β-HSD	Metabolic Disease
HSD17B13-IN-60 (Compound 126) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-60 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163256

HSD17B13-IN-59	17β-HSD	Metabolic Disease
HSD17B13-IN-59 (Compound 177) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-59 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163245

HSD17B13-IN-32	17β-HSD	Metabolic Disease
HSD17B13-IN-32(Compound 67) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-32can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-157613

HSD17B13-IN-5	17β-HSD	Metabolic Disease
HSD17B13-IN-5 (Compound 96) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-5 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-157601

HSD17B13-IN-4	17β-HSD	Metabolic Disease
HSD17B13-IN-4 (Compound 95) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with a K_i value of ≤ 50 nM for the estradiol substrate LCMS. HSD17B13-IN-4 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-163253S

HSD17B13-IN-56-d3	17β-HSD	Metabolic Disease
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162219

HSD17B13-IN-93	17β-HSD	Metabolic Disease
HSD17B13-IN-93 (Compound 9) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-93 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-162217

HSD17B13-IN-91	17β-HSD	Metabolic Disease
HSD17B13-IN-91 (Compound 5) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value for estradiol that is greater than 0.1 μM and less than or equal to 0.5 μM. HSD17B13-IN-91 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-161216

HSD17B13-IN-15	17β-HSD	Metabolic Disease
HSD17B13-IN-15 (Compound 6) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-15 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-161215

HSD17B13-IN-14	17β-HSD	Metabolic Disease
HSD17B13-IN-14 (Compound 4) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-14 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-161214

HSD17B13-IN-12	17β-HSD	Metabolic Disease
HSD17B13-IN-12 (Compound 3) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for both leukotriene B3 and estradiol. HSD17B13-IN-12 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-161213

HSD17B13-IN-11	17β-HSD	Metabolic Disease
HSD17B13-IN-11 (Compound 2) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. HSD17B13-IN-11 can be used in the research of liver diseases, metabolic disorders, or cardiovascular diseases such as NAFLD or NASH, or drug-induced liver injury (DILI) .

HY-173293

ASK1-IN-8	ASK1	Inflammation/Immunology
ASK1-IN-8 (Compound 35) is an orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC₅₀ value of 1.8 nM . In an experimental mouse model of liver injury induced by Acetaminophen (HY-66005), ASK1-IN-8 can significantly reduce the plasma alanine transaminase (ALT) level, protecting the liver . ASK1-IN-8 can be used in research related to liver diseases .

HY-108022

Azemiglitazone 1 Publications Verification MSDC-0602	Mitochondrial Metabolism PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .

HY-162223

HSD17B13-IN-97	17β-HSD	Metabolic Disease
HSD17B13-IN-97 (compound 4) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor with an IC₅₀ value of ≤0.1 µM. HSD17B13-IN-97 has the potential for the research of Nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH) or or drug induced liver injury (DILI) .

HY-163263S1

HSD17B13-IN-80-d2	17β-HSD	Metabolic Disease
HSD17B13-IN-80-d₂ (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-N0385

Gomisin J 3 Publications Verification	NO Synthase AMPK CaMK NF-κB Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .

HY-12538

Graveoline Rutamine	Apoptosis Autophagy Fungal Parasite Reactive Oxygen Species (ROS) Interleukin Related JAK STAT	Infection Inflammation/Immunology Cancer
Graveoline (Rutamine) is an orally active alkaloid with various activities such as antifungal, antiparasitic, anti-inflammatory, and antitumor effects. Graveoline can induce tumor cell apoptosis and autophagy through a reactive oxygen species-mediated pathway. Graveoline has an MIC of 500 μg/mL for Candida albicans. Graveoline can be used in the research of various diseases such as tumors and liver injury .

HY-130437

p-nitro-Pifithrin-α	MDM-2/p53 TGF-β Receptor Caspase	Infection Metabolic Disease
p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease .

Cat. No.	Product Name	Type

HY-Y1147

Diethyl maleate

1 Publications Verification

Maleic acid diethyl ester

Biochemical Assay Reagents

Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter X_{O ^-}. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0385

Gomisin J 3 Publications Verification	Cardiovascular Disease Structural Classification Monophenols Classification of Application Fields Source classification Lignans Phenols Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields	NO Synthase AMPK CaMK NF-κB Keap1-Nrf2
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc .

HY-12538

Graveoline Rutamine	Structural Classification Alkaloids Ruta graveolens Linn. Source classification Rutaceae Quinoline Alkaloids Plants	Apoptosis Autophagy Fungal Parasite Reactive Oxygen Species (ROS) Interleukin Related JAK STAT
Graveoline (Rutamine) is an orally active alkaloid with various activities such as antifungal, antiparasitic, anti-inflammatory, and antitumor effects. Graveoline can induce tumor cell apoptosis and autophagy through a reactive oxygen species-mediated pathway. Graveoline has an MIC of 500 μg/mL for Candida albicans. Graveoline can be used in the research of various diseases such as tumors and liver injury .

HY-N6850

Calenduloside E 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Other Diseases Aralia elata (Miq.) Seem. Plants Endogenous metabolite Disease Research Fields Araliaceae	Apoptosis Pyroptosis AMPK Bcl-2 Family JAK STAT Calcium Channel Interleukin Related TNF Receptor SOD Reactive Oxygen Species (ROS) PPAR
Calenduloside E is a pentacyclic triterpenoid saponin that can be extracted from the bark and roots of Aralia ovata, and has anti-inflammatory and anti-apoptotic activities. Calenduloside E alleviates atherosclerosis by regulating macrophage polarization, improves mitochondrial function by regulating the AMPK-SIRT3 pathway, and alleviates acute liver injury. In addition, Calenduloside E promotes the interaction between L-type calcium channels and Bcl-2 related apoptosis genes, inhibits calcium overload, and alleviates myocardial ischemia/reperfusion injury. Calenduloside E also improves non-alcoholic fatty liver disease by regulating heat shock-dependent pathways, and inhibits ROS mediated JAK1-STAT3 pathways to reduce cellular inflammatory responses .

HY-19696B

Tauroursodeoxycholate dihydrate Maximum Cited Publications 79 Publications Verification Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Structural Classification Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Steroids Cancer	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .

HY-N0806

Sweroside 1 Publications Verification	Filago spathulata Presl. Structural Classification Monophenols Classification of Application Fields Labiatae Phenols Metabolic Disease Plants Disease Research Fields	Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP
Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N1431

Tabersonine 2 Publications Verification	Apocynaceae Alkaloids Structural Classification Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK
Tabersonine is a selective, orally active NLRP3 inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-12538R

Graveoline (Standard)	Structural Classification Alkaloids Ruta graveolens Linn. Source classification Rutaceae Quinoline Alkaloids Plants	Reference Standards Apoptosis Autophagy Fungal Parasite Reactive Oxygen Species (ROS) Interleukin Related JAK STAT
Graveoline (Standard) is the analytical standard of Graveoline (HY-12538). This product is intended for research and analytical applications. Graveoline (Rutamine) is an orally active alkaloid with various activities such as antifungal, antiparasitic, anti-inflammatory, and antitumor effects. Graveoline can induce tumor cell apoptosis and autophagy through a reactive oxygen species-mediated pathway. Graveoline has an MIC of 500 μg/mL for Candida albicans. Graveoline can be used in the research of various diseases such as tumors and liver injury .

HY-N15722

9-O-β-D-Glucopyranosyl-3,4-dimethoxy-cinnamic acid	Structural Classification other families Microlepia speluncae (L.) Moore Simple Phenylpropanols Source classification Phenylpropanoids Plants Saccharides Monosaccharides	Reactive Oxygen Species (ROS)
9-O-β-D-Glucopyranosyl-3,4-dimethoxy-cinnamic acid is an orally active phenylpropanoid glycoside found in Microlepia pilosissima, acting as an antioxidant. 9-O-β-D-Glucopyranosyl-3,4-dimethoxy-cinnamic acid shows a DPPH radical scavenging activity with an ED₅₀ value of 38.1 μM. 9-O-β-D-Glucopyranosyl-3,4-dimethoxy-cinnamic acid is promising for research of oxidative stress-related diseases such as inflammation and liver injury .

HY-N0806R

Sweroside (Standard)	Filago spathulata Presl. Structural Classification Monophenols Labiatae Phenols Plants	Reference Standards Keap1-Nrf2 AMPK Sirtuin NF-κB NOD-like Receptor (NLR) Pyroptosis Apoptosis Autophagy PARP
Sweroside (Standard) is the analytical standard of Sweroside (HY-N0806). This product is intended for research and analytical applications. Sweroside is an iridoid glycoside that targets multiple targets, including the Keap1/Nrf2 axis, NLRP3 inflammasome, SIRT1, NF-κB, AMPK/mTOR pathway, and caspase family. Sweroside promotes Nrf2 nuclear translocation by competitively binding to Keap1. Sweroside also inhibits oxidative stress and NLRP3-mediated pyroptosis by activating Nrf2, inhibits NF-κB inflammatory pathway by activating SIRT1, and promotes autophagy and induces caspase-dependent apoptosis via the AMPK/mTOR pathway. Sweroside has antioxidant, anti-inflammatory, anti-apoptotic, and lipid metabolism regulating activities, and can be used in the research of myocardial ischemia-reperfusion injury, leukemia, acute lung injury, non-alcoholic fatty liver disease, and other fields .

HY-N1431A

Tabersonine hydrochloride	Apocynaceae Alkaloids Structural Classification Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK
Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer .

HY-15449

Kaempferide 3 Publications Verification Kaempferol 4'-O-methyl ether	Infection Flavonols Structural Classification Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Alpinia officinarum Hance Plants Disease Research Fields Zingiberaceae	Estrogen Receptor/ERR Autophagy Bacterial Influenza Virus Apoptosis PI3K Akt GSK-3 FOXO β-catenin
Kaempferide is an orally active flavonol isolated from Hippophae rhamnoides L. Kaempferide has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. Kaempferide induces apoptosis. Kaempferide promotes osteogenesis through antioxidants and can be used in osteoporosis research .

Cat. No.	Product Name	Chemical Structure

HY-163253S

HSD17B13-IN-56-d3
HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

HY-163263S1

HSD17B13-IN-80-d2

HSD17B13-IN-80-d₂ (Compound 200) is the the deuterium labeled HSD17B13-IN-80 (HY-163263). HSD17B13-IN-80 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC₅₀ value of ≤ 0.1 μM for estradiol. HSD17B13-IN-80 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

liver injury diseases

Inhibitors & Agonists

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products